JCR Pharmaceuticals (JCRRF) News Today $4.70 0.00 (0.00%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 2, 2024 | americanbankingnews.comJCR Pharmaceuticals Co., Ltd. (OTCMKTS:JCRRF) Short Interest Down 7.3% in AugustJuly 19, 2024 | businesswire.comJCR Pharmaceuticals Highlights Innovative Gene Therapy Research at the 7th International Forum of Lysosomal DisordersMay 25, 2024 | finance.yahoo.comModalis Therapeutics Corporation (4883.T)March 19, 2024 | finance.yahoo.comJCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with AlexionMarch 2, 2024 | morningstar.comJCR Pharmaceuticals Co Ltd 4552February 29, 2024 | finance.yahoo.comJCR Pharmaceuticals Celebrates Rare Disease Day 2024 and Highlights Its Commitment to the Rare Disease CommunityFebruary 14, 2024 | finance.yahoo.comJCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage DisordersJanuary 25, 2024 | markets.businessinsider.comJCR Pharmaceuticals earnings preview: what Wall Street is expectingJanuary 25, 2024 | finance.yahoo.comJCR Pharmaceuticals to Present at the 20th Annual WORLDSymposium™ 2024December 21, 2023 | finance.yahoo.comJCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo® TechnologyDecember 21, 2023 | finance.yahoo.comJCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy CollaborationDecember 15, 2023 | finance.yahoo.comU.S. FDA Grants Orphan Drug Designation to JR-441 for the Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)November 13, 2023 | msn.comJCR Pharmaceuticals doses first patient in MPS IIIA trialOctober 24, 2023 | markets.businessinsider.comJCR Pharmaceuticals earnings preview: what to expectSeptember 29, 2023 | finance.yahoo.comJCR Pharmaceuticals Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)September 28, 2023 | marketwatch.comJCR Pharmaceuticals Shares Jump After It Raises Earnings GuidanceJuly 27, 2023 | markets.businessinsider.comHere's what Wall Street expects from JCR Pharmaceuticals's earnings reportMay 17, 2023 | investing.comJCR Pharmaceuticals Co Ltd (4552)May 11, 2023 | news.yahoo.comItaly's Angelini invests up to $506 million in Japan's JCR for epilepsy drugMay 11, 2023 | reuters.comItaly's Angelini invests up to $506 mln in Japan's JCR for epilepsy drugApril 3, 2023 | finance.yahoo.comJCR Pharmaceuticals Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoⓇ for Neurodegenerative Disease Get JCR Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for JCRRF and its competitors with MarketBeat's FREE daily newsletter. Email Address War on Elon Escalates… (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. JCRRF Media Mentions By Week JCRRF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JCRRF News Sentiment▼0.890.55▲Average Medical News Sentiment JCRRF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JCRRF Articles This Week▼20▲JCRRF Articles Average Week Get JCR Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for JCRRF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AZNCF News DSNKY News KYKOF News MAYNF News OPHLY News OTSKF News RHHVF News SNYNF News VRBCF News LLY News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:JCRRF) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JCR Pharmaceuticals Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share JCR Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.